title: Short-term application of doxorubicin chemotherapy immunosuppressive side effects for composite tissue allotransplantation.
abstract: BACKGROUND
  Adjuvant chemotherapy is often required for the treatment of bone cancers after tumor resection, which often results in a large continuity defect. The immunosuppressive side effects could instead be exploited to allow immediate reconstruction with a composite tissue allograft (CTA) that would provide for replacement of tissues. We used a short course of doxorubicin to achieve a novel method of immunosuppression in a rat model undergoing CTA to create an immunological environment for allograft survival.
  
  
  METHODS
  The Institutional Animal Care and Use Committee-approved protocol consisted of 3 experimental groups. Groups 2 and 3 consisted of Brown Norway rats (n = 5) as allograft donors and Lewis rats (n = 5) as transplant recipients. An abdominal wall CTA was harvested off the superficial inferior epigastric vessels. Doxorubicin therapy was administered in group 3 animals. Survival of the CTA was assessed by physical examination and histological analysis.
  
  
  RESULTS
  Allotransplant without treatment showed complete clinical and histologic rejection by day 7. Allotransplant rats treated with doxorubicin had clinically and histologically normal grafts through day 10. Kaplan-Meier survival analysis showed a statistically significant difference, with increased CTA survival time to end point with doxorubicin treatment, from a mean of 8.8 days in group 2 to 16.4 days in group 3.
  
  
  CONCLUSIONS
  Allotransplant flaps without treatment developed complete clinical and histological rejection. The allotransplant group which received doxorubicin showed a delay of allograft rejection with an 86% increased CTA graft survival time. This demonstrates the feasibility of the immunosuppression side effect caused by chemotherapy to prevent rejection of a CTA.
authors.affiliation: Division of Plastic and Reconstructive Surgery, University of Maryland School of Medicine, Baltimore, MD, USA.
authors.forename: Helen G
authors.initials: HG
authors.lastname: Hui-Chou
authors.forename: J Bryce
authors.initials: JB
authors.lastname: Olenczak
authors.forename: Cinthia B
authors.initials: CB
authors.lastname: Drachenberg
authors.forename: Sofia M
authors.initials: SM
authors.lastname: Shea
authors.forename: Eduardo D
authors.initials: ED
authors.lastname: Rodriguez
mesh_terms: D034861:Abdominal Wall / Q000601:surgery; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000601:surgery; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D006082:Graft Enhancement, Immunologic / Q000379:methods*; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D051381:Rats; D017207:Rats, Sprague-Dawley; D019651:Plastic Surgery Procedures / Q000379:methods*; D013524:Surgical Flaps / Q000276:immunology / Q000473:pathology; D014184:Transplantation, Homologous
chemical_list: D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D004317:Doxorubicin